Liraglutide, but not vildagliptin, restores normoglycaemia and insulin content in the animal model of type 2 diabetes, Psammomys obesus

Regulatory Peptides

Volumn 160, Issue 1-3, 2010, Pages 106-114

  Vedtofte, Louise ^a   Bodvarsdottir, Thóra B ^b   Gotfredsen, Carsten F ^b   Karlsen, Allan E ^b   Knudsen, Lotte B ^b   Heller, R Scott ^a  

^a HAGEDORN RESEARCH INSTITUTE   (Denmark)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Diabetes; GLP 1; Insulin; Liraglutide; Pancreas; Psammomys obesus; Vildagliptin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; VILDAGLIPTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; LOW CALORY DIET; MALE; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; PSAMMOMYS OBESUS; STEREOMETRY; TREATMENT DURATION;

ADAMANTANE; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GERBILLINAE; GLUCAGON-LIKE PEPTIDE 1; IMMUNOHISTOCHEMISTRY; INSULIN; MALE; NITRILES; PANCREAS; PYRROLIDINES; REFERENCE STANDARDS;

ANIMALIA; PSAMMOMYS OBESUS;

EID: 74749085671     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2009.12.005     Document Type: Article

References (55)

1. Weyer C., Bogardus C., and Mott D.M. Pratley RE The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104 (1999) 787-794
2. Zeggini E., Scott L.J., Saxena R., Voight B.F., Marchini J.L., Hu T., de Bakker P.I., Abecasis G.R., Almgren P., Andersen G., Ardlie K., Bostrom K.B., Bergman R.N., Bonnycastle L.L., Borch-Johnsen K., Burtt N.P., Chen H., Chines P.S., Daly M.J., Deodhar P., et al. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 40 (2008) 638-645
3. Kaiser N., Yuli M., Uckaya G., Oprescu A.I., Berthault M.F., Kargar C., Donath M.Y., Cerasi E., and Ktorza A. Dynamic changes in {beta}-cell mass and pancreatic insulin during the evolution of nutrition-dependent diabetes in psammomys obesus: impact of glycemic control. Diabetes 54 (2005) 138-145
4. Kalderon B., Gutman A., Levy E., Shafrir E., and Adler J.H. Characterization of stages in development of obesity-diabetes syndrome in sand rat (Psammomys obesus). Diabetes 35 (1986) 717-724
5. Marquie G., Duhault J., and Jacotot B. Diabetes mellitus in sand rats (Psammomys obesus). Metabolic pattern during development of the diabetic syndrome. Diabetes 33 (1984) 438-443
6. Schmidt-Nielsen K., Haines H.B., and Hackel D.B. Diabetes mellitus in the sand rat induced by standard laboratory diets. Science 143 (1964) 689-690
7. Shafrir E., Ziv E., and Kalman R. Nutritionally induced diabetes in desert rodents as models of type 2 diabetes: Acomys cahirinus (spiny mice) and Psammomys obesus (desert gerbil). Ilar J 47 (2006) 212-224
8. Walder K.R., Fahey R.P., Morton G.J., Zimmet P.Z., and Collier G.R. Characterization of obesity phenotypes in Psammomys obesus (Israeli sand rats). Int J Exp Diabetes Res 1 (2000) 177-184
9. Deacon C.F., Pridal L., Klarskov L., Olesen M., and Holst J.J. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 271 (1996) E458-E464
10. Orskov C., Holst J.J., Knuhtsen S., Baldissera F.G., Poulsen S.S., and Nielsen O.V. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 119 (1986) 1467-1475
11. Nauck M.A., Kleine N., Orskov C., Holst J.J., Willms B., and Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36 (1993) 741-744
12. Nauck M.A., Wollschlager D., Werner J., Holst J.J., Orskov C., Creutzfeldt W., and Willms B. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 39 (1996) 1546-1553
13. Nauck M.A., Weber I., Bach I., Richter S., Orskov C., Holst J.J., and Schmiegel W. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients. Diabet Med 15 (1998) 937-945
14. Todd J.F., Wilding J.P., Edwards C.M., Khan F.A., Ghatei M.A., and Bloom S.R. Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 27 (1997) 533-536
15. Knudsen L.B., Kiel D., Teng M., Behrens C., Bhumralkar D., Kodra J.T., Holst J.J., Jeppesen C.B., Johnson M.D., de Jong J.C., Jorgensen A.S., Kercher T., Kostrowicki J., Madsen P., Olesen P.H., Petersen J.S., Poulsen F., Sidelmann U.G., Sturis J., Truesdale L., et al. Small-molecule agonists for the glucagon-like peptide 1 receptor. Proc Natl Acad Sci USA 104 (2007) 937-942
16. Garber A., Henry R., Ratner R., Garcia-Hernandez P.A., Rodriguez-Pattzi H., Olvera-Alvarez I., Hale P.M., Zdravkovic M., and Bode B. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373 9662 (2009) 473-481
17. Ribel U., Larsen M.O., Rolin B., Carr R.D., Wilken M., Sturis J., Westergaard L., Deacon C.F., and Knudsen L.B. NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. Eur J Pharmacol 451 (2002) 217-225
18. Rolin B., Larsen M.O., Gotfredsen C.F., Deacon C.F., Carr R.D., Wilken M., and Knudsen L.B. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 283 (2002) E745-E752
19. Bregenholt S., Moldrup A., Blume N., Karlsen A.E., Nissen Friedrichsen B., Tornhave D., Knudsen L.B., and Petersen J.S. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Biophys Res Commun 330 (2005) 577-584
20. Ahren B., Landin-Olsson M., Jansson P.A., Svensson M., Holmes D., and Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89 (2004) 2078-2084
21. Drucker D.J., Philippe J., Mojsov S., Chick W.L., and Habener J.F. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 84 (1987) 3434-3438
22. Li Y., Hansotia T., Yusta B., Ris F., Halban P.A., and Drucker D.J. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278 (2003) 471-478
23. Perfetti R., Zhou J., Doyle M.E., and Egan J.M. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 141 (2000) 4600-4605
24. Song W.J., Schreiber W.E., Zhong E., Liu F.F., Kornfeld B.D., Wondisford F.E., and Hussain M.A. Exendin-4 stimulation of cyclin A2 in beta-cell proliferation. Diabetes 57 (2008) 2371-2381
25. Tourrel C., Bailbe D., Meile M.J., Kergoat M., and Portha B. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 50 (2001) 1562-1570
26. Tourrel C., Bailbe D., Lacorne M., Meile M.J., Kergoat M., and Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes 51 (2002) 1443-1452
27. Xu G., Stoffers D.A., Habener J.F., and Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48 (1999) 2270-2276
28. Xu G., Kaneto H., Lopez-Avalos M.D., Weir G.C., and Bonner-Weir S. GLP-1/exendin-4 facilitates beta-cell neogenesis in rat and human pancreatic ducts. Diabetes Res Clin Pract 73 1 (2006) 107-110
29. Holz G.G., and Chepurny O.G. Diabetes outfoxed by GLP-1?. Sci STKE 268 (2005) pe2
30. Barilla D., He Y., Balez B., Bullock J., Ho Y., Guiterrez M., and Ligueros-Saylan M. No pharmacokinetic interactions or acute clinical safety issues preclude combination of the DPP-4 inhibitor LAF237 with glyburide. 64th Scientific Session of American Diabetes Association Orlando, FL, p. 1967-PO (2004)
31. Ahren B., Gomis R., Standl E., Mills D., and Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2874-2880
32. Ahren B., Winzell M.S., Burkey B., and Hughes T.E. Beta-cell expression of a dominant-negative HNF-1alpha compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice. Eur J Pharmacol 521 (2005) 164-168
33. Ahren B., Winzell M.S., Wierup N., Sundler F., Burkey B., and Hughes T.E. DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell-specific overexpression of human islet amyloid polypeptide. Regul Pept 143 (2007) 97-103
34. Burkey, B.F., Li, X., Bolognese, L., Balkan, B., Mone, M., Russell, M., Hughes, T.E., Wang, P.R. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. J Pharmacol Exp Ther 2005;315:688-69541. 35. Flock, G., Baggio, L.L., Longuet, C., Drucker, D.J. Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 2007; 56:3006-3013.
35. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85 (1999) 9-24
36. Cheng Q., Law P.K., de Gasparo M., and Leung P.S. Combination of the dipeptidyl peptidase IV inhibitor LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] with the angiotensin II type 1 receptor antagonist valsartan [N-(1-oxopentyl)-N-[[2′-(1H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl]methyl]-L-valine] enhances pancreatic islet morphology and function in a mouse model of type 2 diabetes. J Pharmacol Exp Ther 327 (2008) 683-691
37. Moritoh Y., Takeuchi K., Asakawa T., Kataoka O., and Odaka H. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Eur J Pharmacol 588 (2008) 325-332
38. Mu J., Woods J., Zhou Y.P., Roy R.S., Li Z., Zycband E., Feng Y., Zhu L., Li C., Howard A.D., Moller D.E., Thornberry N.A., and Zhang B.B. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55 (2006) 1695-1704
39. Pospisilik J.A., Martin J., Doty T., Ehses J.A., Pamir N., Lynn F.C., Piteau S., Demuth H.U., McIntosh C.H., and Pederson R.A. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52 (2003) 741-750
40. Bödvarsdóttir T.B., Jensen-Holm H.B., Jørgensen M.S., Buccholz T.T., and Knudsen L.B. Liraglutide reverses diabetes in Psammomys obesus, a model of type 2 diabetes. 65th Scientific Session of American Diabetes Association San Diego, CA (2005)
41. Gundersen H.J. The smooth fractionator. J Microsc 207 (2002) 191-210
42. Pridal L., Ingwersen S.H., Larsen F.S., Holst J.J., Adelhorst K., and Kirk O. Comparison of sandwich-linked immunoabsorbent assay radioimmunoassay for determination of exogenous glucagon-like peptide-1(7-36)amide in plasma. J Pharm Biomed Anal 13 (1995) 841-850
43. Wilken M., Larsen F.S., Buckley D., and Holst J.J. New highly specific immunoassay for glucagon-like peptide 1 (GLP-1). Diabetologia 42 (1991) A196
44. Poulsen F., and Jensen K.B. A luminescent oxygen channeling immunoassay for the determination of insulin in human plasma. J Biomol Screen 12 (2007) 240-247
45. Drucker D.J. Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 144 (2003) 5145-5148
46. Friedrichsen B.N., Neubauer N., Lee Y.C., Gram V.K., Blume N., Petersen J.S., Nielsen J.H., and Moldrup A. Stimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways. J Endocrinol 188 (2006) 481-492
47. Gradwohl G., Dierich A., LeMeur M., and Guillemot F. Neurogenin3 is required for the development of the four endocrine cell lineages of the pancreas. Proc Natl Acad Sci USA 97 (2000) 1607-1611
48. Farilla L., Hui H., Bertolotto C., Kang E., Bulotta A., Di Mario U., and Perfetti R. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143 (2002) 4397-4408
49. Uckaya G., Delagrange P., Chavanieu A., Grassy G., Berthault M.F., Ktorza A., Cerasi E., Leibowitz G., and Kaiser N. Improvement of metabolic state in an animal model of nutrition-dependent type 2 diabetes following treatment with S 23521, a new glucagon-like peptide 1 (GLP-1) analogue. J Endocrinol 184 (2005) 505-513
50. Li Y., Cao X., Li L.X., Brubaker P.L., Edlund H., and Drucker D.J. beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes 54 (2005) 482-491
51. Leibowitz G., Ferber S., Apelqvist A., Edlund H., Gross D.J., Cerasi E., Melloul D., and Kaiser N. IPF1/PDX1 deficiency and beta-cell dysfunction in Psammomys obesus, an animal With type 2 diabetes. Diabetes 50 (2001) 1799-1806
52. Gustavsen C.R., Chevret P., Krasnov B., Mowlavi G., Madsen O.D., and Heller R.S. The morphology of islets of Langerhans is only mildly affected by the lack of Pdx-1 in the pancreas of adult Meriones jirds. Gen Comp Endocrinol 159 (2008) 241-249
53. Bock T., Pakkenberg B., and Buschard K. The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211. APMIS 111 12 (2003) 1117-1124
54. Wang X., Cahill C.M., Pineyro M.A., Zhou J., Doyle M.E., and Egan J.M. Glucagon-like peptide-1 regulates the beta cell transcription factor, PDX-1, in insulinoma cells. Endocrinology 140 (1999) 4904-4907
55. Wang Y., Perfetti R., Greig N.H., Holloway H.W., DeOre K.A., Montrose-Rafizadeh C., Elahi D., and Egan J.M. Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J Clin Invest 99 (1997) 2883-2889